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Statement of translational relevance
The anti-EGFR monoclonal antibody cetuximab is effective for the treatment of patients with 'RAS' wild-type metastatic colorectal cancer (mCRC). Unfortunately, responses are transient and most patients develop acquired resistance. In the present study, we analysed the genetic profile of clinical specimens and preclinical models of acquired resistance to cetuximab, revealing a complex pattern of mutations in both EGFR and its downstream effectors, KRAS, NRAS, BRAF and PIK3CA. We discovered five novel point mutations in the ectodomain of EGFR, which confer resistance to cetuximab. Of note, only a subset of these EGFR variants remains sensitive to panitumumab. Accordingly, identification patient-specific mechanisms of resistance to EGFR blockade will be paramount to design additional lines of therapy.
Introduction
Monoclonal antibodies (moAbs) directed against the epidermal growth factor receptor (EGFR) --cetuximab and panitumumab--provide significant survival benefit to patients with RAS wild-type metastatic colorectal cancer (mCRC) and are now standard components of treatment regimens for these patients, either alone or in combination with chemotherapy.
However, the duration of this response is only transient and does not last more than 3 to 12 months, after which secondary resistance occurs (1) (2) (3) (4) (5) . Definition of the molecular changes underlying acquired resistance to anti-EGFR antibodies is needed to improve clinical benefit and devise further lines of treatment. Molecular profiling of patient samples and preclinical models have previously defined a number of mechanisms of secondary resistance. The most common event is the emergence of KRAS and NRAS mutations which occurs in approximately 50-80% of the cases (6) (7) (8) (9) (10) . Other escape routes include acquisition of the S492R mutation in the ectodomain of EGFR (10) (11) (12) (13) , as well as amplification of tyrosine kinase receptor genes HER2 or MET (14, 15) . Interestingly, recent data indicate co-existence of several molecular mechanisms of secondary resistance within an individual patient (6-10, 12, 16) .
To identify yet unknown molecular events leading to anti-EGFR treatment failure, we investigated the role of mutations in the EGFR signaling pathway on the acquisition of resistance to cetuximab in CRC patients and cellular models. Our findings suggest that we have yet to fully characterize the complete spectrum of genetic variants through which colorectal tumors evade EGFR blockade. The data presented here will help design additional therapeutic strategies to circumvent resistance of CRC patients who receive EGFR targeted antibodies.
Materials and Methods

Tumor samples and patients
All mCRC consenting patients treated with anti-EGFR moAb at Hospital del Mar between January 2010 and June 2013 were included in this study. In the analysis, we only included patients who had good quality paired pre-and post-treatment biopsies and who acquired resistance to anti-EGFR based-therapy defined as progression disease following a) complete response or partial response or b) stable disease for more than 16 weeks.
Response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) (17) . Our study included re-biopsy following treatment failure in patients who consented to this extra procedure. Re-biopsies at the time of progression were obtained from the most accessible lesion with less potential risk of related complications for the patient according to ethical considerations. Pre-treatment sample was obtained from the regular diagnosis procedure. In this study, we included nine cases (patients #21 to #28 and patient #36) that had been previously assessed for EGFR S492R, KRAS exon 2, BRAF V600E and PIK3CA mutations by Sanger sequencing (12) and that in the current work were analyzed for a broader panel of mutations as specified below using more sensitive sequencing technologies. Biological samples were obtained from Parc de Salut Mar Biobank (MARBiobanc). This study was approved by the local Ethics Board (CEIC-2012/4741/I). All participating patients signed written informed consent.
Mutational analysis in tissue samples
DNA extraction from tumoral samples was performed as previously described (12) .
Mutational analysis of KRAS (exons 2, 3 and 4), BRAF (exon15), NRAS (exons 2 and 3),
PIK3CA (exons 9 and 20) and EGFR (exon 12) was performed by Sanger sequencing using BigDye v3.1 (Applied Biosystems, Foster City, CA) following manufacturer's instructions and analyzed on a 3500Dx Genetic Analyzer (Applied Biosystems). KRAS (exons 3 and 4) and NRAS (exons 2, 3 and 4) were also analyzed by pyrosequencing (Qiagen) and KRAS (exon 2) was also assessed by Therascreen real time PCR (Qiagen) following the manufacturer's instructions. All cases were also screened by pyrosequencing using a Next Generation Sequencing (NGS) 454 GS Junior platform (Roche Applied Science, Mannheim, Germany). Processed and quality-filtered reads were analyzed using the GS Amplicon Variant Analyzer software version 2.5p1 (Roche). Mutations detected by NGS were confirmed by competitive allele-specific TaqMan® PCR (CAST-PCR, Applied Biosystems) when specific assays were available. Generation of resistant cells utilized in this manuscript has already been previously described (6, 9) . CCK81 cetuximab-resistant derivatives were obtained by increasing the cetuximab dosage stepwise from 680 nM to 1.4 µM during the course of six months.
Cell culture and generation of resistant cells
Mutational analysis in cell lines
Genomic DNA samples were extracted by Wizard® SV Genomic DNA Purification System (Promega). For Sanger Sequencing, all samples were subjected to automated sequencing by ABI PRISM 3730 (Applied Biosystems). Primer sequences are listed elsewhere (6, 9) .
The following genes and exons were analyzed: KRAS (exons 2, 3 and 4), NRAS (exons 2 and 3), PIK3CA (exons 9 and 20), BRAF (exon 15), EGFR (exon12). All mutations were confirmed twice, starting from independent PCR reactions.
Drug assays
Cetuximab was obtained from the Pharmacy at Niguarda Ca' Granda Hospital, Milan, Italy.
Cell lines were seeded in 100 µL medium at the following densities (2x10 3 for DiFi, 1.5 x10 3 for LIM1215, HCA-46, NCIH508 and OXCO-2, 3x10 3 for CCK81) in 96-well culture plates. After serial dilutions, cetuximab in serum-free medium was added to cells, and medium-only wells were included as controls. Plates were incubated at 37°C in 5% CO2 for 6 days, after which cell viability was assessed by ATP content using the CellTiter-Glo® Luminescent Assay (Promega).
DNA constructs and mutagenesis
The pLX301-EGFR WT construct was a generous gift from Dr. C. Sun and Prof R.
Bernards (NKI, Amsterdam). EGFR mutants containing the 6 point mutations (R451C, S464L, G465R, K467T, I491M and S492R) were constructed using the QuikChange® II site-directed mutagenesis kits from Agilent Technologies with pLX301-EGFR WT plasmid as the template DNA. The presence of mutations was confirmed by DNA sequencing.
Droplet Digital PCR
Isolated gDNA was amplified using ddPCR™ Supermix for Probes (Bio-Rad) using KRAS, EGFR probes and primers sequences are available upon request.
Molecular Simulations
Input coordinates for the structure of cetuximab bound to wild type sEGFR (extracellular part) were taken from PDB:1YY9 (19) . The system was parameterized using the Amber12 force field (20) and solvated and neutralized in a TIP3P water box. Energy minimization was conducted under NPT conditions at 1 atm, 298K and a cutoff of 9 Ǻ, with rigid bonds and PME for long-range electrostatics. Potential energy minimization was run for 2ps.
During minimization the heavy protein atoms were not restrained. The simulation was run using ACEMD (21) on a local GPU-equipped workstation.
Flow Cytometry
To measure cetuximab and panitumumab binding to cells expressing mutant EGFR, we EGFR binding was analyzed using the FACScan flow Cytometer.
Protein detection
We subjected total cell lysates to Western blot analysis as previously reported (12) . The phospho EGFR antibody (Y1068) was purchased from Cell Signalling Technology.
Results
Emergence of EGFR ectodomain mutations in patients treated with cetuximab
Thirty-seven consecutive patients with metastatic colorectal cancer who had acquired resistance to cetuximab after an initial response to the treatment and had good quality paired pre-and post-treatment specimens were included in this study. Tumor biopsy obtained during the regular diagnosis procedure was used as the pre-treatment sample. In most cases this sample was obtained from the primary tumor during routine colonoscopy.
Biopsies at progression were taken from liver (21 samples), lung (6), bone (2), peritoneum (3), colon-rectum (3), retroperitoneal lymph node (1) and subcutaneous node (1) with ultrasound guidance, CT-scan guidance, or colonoscopy in the case of colon-rectum lesions. There were no major biopsy-related complications. Patients' clinical characteristics are showed in Supplementary Table S1 .
All pre-treatment biopsies were screened for mutations in KRAS, NRAS and BRAF by Sanger and pyrosequencing as part of routine clinical practice at Hospital del Mar (Barcelona). Mutations in PIK3CA and EGFR were also assessed as part of this study. All pre-treatment biopsies were wild type except for three samples that harbored mutations in PIK3CA. Since PIK3CA mutations do not preclude response to anti-EGFR therapy, these patients were treated with cetuximab-based regimens. Post-treatment tissue samples were analyzed for the same mutations using the same sequencing platforms. In total, we detected the emergence of 31 mutations in post-treatment biopsies from 20 patients ( Table 1 ). The additional 17 post treatment samples did not reveal variants in any of the genes we analyzed. In seven cases, mutations in different genes were detected in the same tissue sample (median of detected mutations within the same specimen 2, range 1-5) (Table 1) .
Acquired mutations were found in NRAS (9 events) and KRAS genes (8 events) followed by mutations in PIK3CA (6 events) and BRAF (3 events). Interestingly, mutations in RAS frequently occurred in exons 3-4 (67% of NRAS and 50% of KRAS mutations). Of note, mutations in PIK3CA always coexisted with other mutations within the same sample.
Notably, in addition to 'RAS' gene mutations the molecular analysis revealed the emergence of multiple alleles in the EGFR extracellular domain. The previously reported EGFR S492R variant was detected in three patients. Of note, EGFR mutations were accompanied by gene amplification in both the pre-and the post-treatment specimen from two of these patients (data not shown); in the third patient, EGFR gene copy number was not assessed due to lack of sufficient tissue for FISH analysis.
Two novel mutations located in exon 12 of the EGFR gene were discovered by the analysis of post treatment samples. Patient #31 harboured an A -> C substitution at codon 1400 that caused a substitution of a lysine to threonine at aminoacid 467 (p.K467T). The post-cetuximab biopsy from patient #35 harbored a C -> A substitution at codon 1351, resulting in an arginine to cysteine substitution at aminoacid 451 (p.R451C) ( Table 1 and Supplementary Fig. S1 ).
EGFR ectodomain mutations and acquired resistance to cetuximab in CRC cell models
We previously reported that acquisition of resistance in CRC cells is associated with emergence of KRAS, BRAF and NRAS activating mutations (6, 9, 12) . To discover additional mechanisms of resistance to EGFR blockade we exploited 5 CRC cell lines (DiFi, LIM1215, HCA-46, NCIH508, OXCO-2 and CCK81), which are highly sensitive to cetuximab ( Supplementary Fig. S2 ). These cell lines are wild type for KRAS, NRAS, BRAF
and PIK3CA with the exception of NCIH508, which displays the p.E545K PIK3CA mutation. Altogether, these cell models recapitulate the molecular features of tumors from CRC patients likely to respond to anti EGFR therapies. For each line, at least five million cells were exposed continuously to cetuximab until resistant populations emerged ( Supplementary Fig. S2 ). To define molecular mechanisms underlying acquisition of resistance, we initially performed Sanger sequencing of genes involved in regulation of the EGFR signalling pathway (EGFR, KRAS, BRAF, NRAS, and PIK3CA). In accordance with our previous reports, resistant populations often displayed KRAS, BRAF and NRAS mutations (Table 2) (9). All of these alleles were detected in the resistant cells but not in the corresponding parental population from which they originated. Importantly, in several occasions multiple genetic alterations were concomitantly present in the resistant cell population ( Fig. S3 ). Considering that the resistant derivatives are polyclonal, and in light of the limited sensitivity of the Sanger sequencing method, we postulated that variants present in less than 20% of the cell populations might have remained undetected.
To identify mutations present at low frequency we employed droplet digital PCR (ddPCR)
which is known to have a mutant/wild type sensitivity of 1:20000. ddPCR probes were designed and individually validated using control mutant DNA to detect EGFR variants previously identified in tumor biopsy or cell lines (Supplementary Table S2 ). This analysis unveiled the presence 3 new EGFR variants (S464L, G465R, and I491M) that were not detected by Sanger sequencing in resistant cell populations (Table 2 and Supplementary Table S3 ). The ddPCR approach could not be performed in tissue samples since there was no sufficient material available. Overall, the mutational landscape of cell lines with acquired resistance to cetuximab, recapitulate the molecular profiles of tumors that relapsed upon cetuximab treatment.
Structural model analysis of EGFR ectodomain mutations
To understand how the EGFR ectodomain mutations detected in tumor samples and cell lines could drive resistance to EGFR blockade we performed computational structurebased analyses. With the exception of R451C, the EGFR mutations are located in the receptor region, which has been shown to interact with cetuximab (Fig. 1A) . More specifically, the S464L, G465R, K467T, I491M and S492R mutations lie in the middle of the surface recognized by the antibody (Fig. 1B) and therefore modifications of this interface has the potential to affect complex formation. Of these five mutations, three appear to disrupt favourable interactions, namely S464L, K467T, and I491M. The polar aminoacid S464 is within H-bond distance from the carbonyl backbone of Y102 and the phenolic OH-group of Y104 (Fig. 1C) . Replacement by a hydrophobic bulky aminoacid as leucine (S464L) has the potential to disrupt the network. Analogously, the positively charged aminoacid K467 is involved in a stabilizing salt bridge with E58 (Fig. 1C) . Insertion of a polar but neutral aminoacid as threonine K467T, although still permitting the H-bond E58, would affect the favourable electrostatic interaction. Residue I491 is a rather large, aliphatic residue located in a hydrophobic cavity mainly formed by aromatic aminoacids (Fig. 1C) . Although the side chains present similar size, methionine (I491M) is a polar aminoacid and would be unfavourably located in a nonpolar environment. The other two mutations (G465R and S492R) involve the change from rather small, polar and uncharged side chain to a large and electrically charged side chain in arginine (Fig. 1C) 
(13).
R451C is the only mutation not located in the cetuximab-binding site, however, the mutation could lead to critical structural changes. As the domain IV is formed by a sequence of disulphide bonds, which preserve its tertiary structure, the replacement by a cysteine at that position could perturb one of the disulphide bonds in domain III (C475-C462) possibly forming a new one between domains III and IV (C451-C475). We verified that the distance in the crystal structure between these residues (C451-C475, carbon alpha distance 6.8 Å) is compatible with the formation of a disulphide bond. Indeed, a system setup in this new configuration successfully minimizes to a C451-C475 distance of 5.2 Å. Overall, all identified mutations in EGFR (except R451C) were located in the cetuximab binding epitope.
Biochemical and functional analyses of EGFR ectodomain mutations
To experimentally assess the impact of the EGFR ectodomain mutations on the ability of the receptor to interact with cetuximab we performed forward genetic experiments on a subset of the newly discovered mutations. Wild type and mutant EGFR cDNAs were ectopically expressed in NIH 3T3 cells that lack endogenous EGFR. Flow cytometry was used to establish the extent of cetuximab binding to cells expressing the mutants; wild type EGFR and S492R served as positive and negative controls respectively. These experiments clearly showed that the newly discovered EGFR K467T, R451C, S464L, G465R and I491M mutations were not permissive for binding to cetuximab thus providing functional evidence of their role in driving acquired resistance to EGFR blockade. Of note, the effect of EGFR R451C on cetuximab binding was less prominent compared to the other mutants (Fig. 2) .
To further characterize the functional properties of the EGFR mutations we performed biochemical studies in cells expressing individual mutations. As expected cetuximab abrogated ligand-mediated activation of the wild type receptor, while had no or very limited impact in cells carrying mutated EGFR (S464L, G465R, K467T, I491M and S492R) (Fig. 3) .
Notably, in R451C mutant cells, cetuximab was still capable of inhibiting EGFR phosphorylation (Fig. 3) .
We then examined whether panitumumab, the other anti-EGFR drug approved to treat CRC, was active in cells overexpressing EGFR mutations. As previously described, S492R mutant cells efficiently bound to panitumumab (12) . We found that the K467T and R451C mutants were to some extent permissive for panitumumab binding, while S464L, G465R and I491M mutants did not bind to this antibody (Fig. 2) . Accordingly, biochemical analyses showed that panitumumab prevents EGFR activation in S492R, K467 and R451C mutants (Fig. 3) .
Discussion
We present a comprehensive analysis of mutational changes affecting key members of the EGFR signaling pathway emerging in tumor biopsies of patients treated with cetuximab and in cell models, which acquired resistance to cetuximab in vitro. We found that Arena et al, Table 1 . EGFR pathway mutations in tissue samples from metastatic colorectal cancer patients treated with cetuximab. S464L  G465R  K467T  I491M  S492R   4  5  8  11  13  15  16  17  18  20  21  23  26  27  31  33  34  35  36  37 Arena et al, Table 2 . EGFR pathway mutations in parental and cetuximab resistant cell lines. Arena et al, Figure 1 Arena et al, Figure 2 Arena et al, Figure 3 Arena et al.
Supplementary table and figure legends
Supplementary Table S1 . Clinical characteristics of patients.
Thirty-seven consecutive metastatic colorectal cancer patients that progressed to cetuximab after an initial response and that had good quality pre-and post-treatment 
